Cerenome, Inc. filed a Form 8-K on November 12, 2026, disclosing the appointment of Ronald A. Andrews as Chief Business Officer effective November 9, 2026, and the promotion of Eric Daniels, M.D., to Chief Operating Officer effective November 6, 2026.

Key Highlights

  • New CBO appointment: Ronald A. Andrews, age 67, was named Chief Business Officer of Cerenome, effective November 9, 2026.
  • Prior board role: Mr. Andrews had been a member of Cerenome's board of directors since March 2026 prior to this appointment.
  • Base salary and bonus: Mr. Andrews will receive an initial annual base salary of $344,955 and an initial annual target bonus of 43% of his base salary.
  • Stock option grant: Mr. Andrews was granted an option to purchase up to 92,858 shares of common stock, vesting over 48 monthly installments.
  • COO promotion: Eric Daniels, M.D., was promoted to Chief Operating Officer on November 6, 2026, while continuing as Chief Development Officer; no changes were made to his existing employment agreement or compensation.
  • Severance terms: An involuntary termination of Mr. Andrews entitles him to nine months of monthly base salary, plus his target bonus for that year, plus any unpaid prior-year annual bonus, among other items.

Cerenome Expands Executive Team With Andrews as CBO and Daniels as COO

According to the filing, Cerenome, Inc. (NASDAQ:CNSY) announced two executive leadership changes in early November 2026. Ronald A. Andrews was appointed Chief Business Officer effective November 9, 2026, with responsibility for "advancing enterprise growth strategy, strategic partnerships, corporate development, and business opportunities across the Company's diagnostics, therapeutics, and data analytics platforms," as the filing states. Mr. Andrews' employment agreement, also effective November 9, 2026, stipulates a 29-hour work week during his tenure as CBO.

The filing describes Mr. Andrews as having over 35 years of experience in diagnostics and molecular diagnostics. His background includes serving as President and CEO of Twin Strand Biosciences from April 2023 to July 2024, President and CEO of Oncocyte Inc. from July 2016 to December 2022, and President of the Genetic Sciences Division at Thermo Fisher Scientific/Life Technologies from September 2013 to February 2015. He is currently Founder and Managing Partner of The Bethesda Group and holds board roles at DxCover Inc., Agendia, Inc., Precipio Inc., and SimBioSys, according to the filing.

The stock option granted to Mr. Andrews vests in two tranches: 50% vests in 12 equal monthly installments beginning one month after the grant date, and the remaining 50% vests in 36 equal monthly installments thereafter, subject to continued service. The exercise price per share is equal to the fair market value of the common stock on the date of grant, the filing states. Separately, Eric Daniels, M.D., was promoted to Chief Operating Officer on November 6, 2026, while retaining his role as Chief Development Officer. The filing notes that no changes were made to Dr. Daniels' employment agreement or compensation in connection with the promotion.

What Was Disclosed

Cerenome disclosed the appointment of Ronald A. Andrews as Chief Business Officer with a $344,955 annual base salary and an option for 92,858 shares, as well as the promotion of Eric Daniels, M.D., to Chief Operating Officer with no compensation changes, in an 8-K covering events of November 6 and November 9, 2026.